Kanaph Therapeutics is dedicated to the research and development of innovative therapeutic molecules aimed at addressing significant unmet medical needs, particularly in the fields of cancer and ophthalmology. The company employs a dual approach in drug discovery, focusing on both large and small molecule development. Their pipeline includes first-in-class bispecific antibodies and best-in-class small molecules that are designed to be distinct from existing therapies. Kanaph's strategy is underpinned by advanced drug discovery technologies that leverage human genomics to identify therapeutic targets, allowing for the creation of differentiated drugs tailored to specific medical challenges.

The bispecific antibodies developed by Kanaph are particularly noteworthy for their application in immuno-oncology and ophthalmology, as they are engineered to overcome the limitations of current treatments. This bispecific approach enables the company to tackle the multifactorial nature of diseases more effectively. Additionally, Kanaph's small molecule drug discovery initiatives focus on creating novel compounds that target specific mutational signaling pathways in hard-to-treat cancers, as well as developing strategies to counteract the immunosuppressive environments fostered by tumors. Through these innovative technologies, Kanaph Therapeutics aims to make significant advancements in therapeutic options for patients.

South Korea

Kanaph Therapeutics is developingtherapeutics for oncology by using bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME).

Kanaph Therapeutics

Company Details